Kevin Meier: Important Nuance in the 2026 AHA/ACC Acute PE Guideline for Patients with Brain Tumors
Kevin Meier, Neurointensivist at Intermountain Medical Center, shared a post on LinkedIn about a recent article by Mark A. Creager et al, adding:
“The 2026 AHA/ACC acute PE guideline added an important nuance for patients with brain tumors and acute PE.
In patients with primary or metastatic brain tumors who are otherwise eligible for oral anticoagulation, a DOAC may be considered over LMWH to reduce ICH risk.
The recommendation is weak, Class 2b, Level C-LD, but it is now explicit in a major PE guideline.
Important caveat: this is not high-level trial evidence.
The signal comes from retrospective observational data, and the apparent ICH advantage of DOACs is clearest in primary brain tumors.
For metastatic brain tumors, the pooled data are more neutral or mixed than definitive.
Separate point: pooled data suggest anticoagulation increases ICH risk in primary brain cancer but not clearly in metastatic disease, even though metastatic tumors carry higher background ICH risk overall.
So this doesn’t make DOACs a universal answer, but it does mean the old LMWH-first reflex deserves another look.”
Title: 2026 AHA/ACC/ACCP/ACEP/CHEST/SCAI/SHM/SIR/SVM/SVN Guideline for the Evaluation and Management of Acute Pulmonary Embolism in Adults: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines
Authors: Mark A. Creager, Geoffrey D. Barnes, Jay Giri, Debabrata Mukherjee, William Schuyler Jones, Allison E. Burnett, Teresa Carman, Ana I. Casanegra, Lana A. Castellucci, Sherrell M. Clark, Mary Cushman, Kerstin de Wit, Jennifer M. Eaves, Margaret C. Fang, Joshua B. Goldberg, Stanislav Henkin, Hillary Johnston-Cox, Sabeeda Kadavath, Daniella Kadian-Dodov, William Brent Keeling, Andrew J.P. Klein, Jun Li, Michael C. McDaniel, Lisa K. Moores, Gregory Piazza, Karen S. Prenger, MS, Steven C. Pugliese, Mona Ranade, Rachel P. Rosovsky, Farla Russo, Eric A. Secemsky, Akhilesh K. Sista, Leben Tefera, Ido Weinberg, Lauren M. Westafer, Michael N. Young
Read the Full Article on American Heart Association Journals
Stay updated with all scientific advances on Hemostasis Today.
-
Mar 28, 2026, 18:32Pooja Choradia: Obesity and Pulmonary Embolism – The Hidden Prothrombotic State
-
Mar 28, 2026, 17:28James Crowley: Precision Cancer Therapy Advances
-
Mar 28, 2026, 17:27Volkmar Weissig: Cellular Uptake of Isolated Mitochondria and Its Implications for Mitochondrial Transfer
-
Mar 28, 2026, 17:25Alan Nurden: FNAIT Remains an Important Clinical Challenge in Inherited Bleeding Disorders
-
Mar 28, 2026, 17:24Michael Baria: Is PRP Disease Modifying in Osteoarthritis?
-
Mar 28, 2026, 17:07Wolfgang Miesbach: How Does Protein S Inhibition Restore Hemostasis in von Willebrand Disease?
-
Mar 28, 2026, 17:01Marcin Czerwinski: Neutralizing Anti-AAV Antibodies in Hemophilia B Gene Therapy
-
Mar 28, 2026, 16:56Sonia Wolf: Reproductive Outcomes in Women with Sickle Cell Disease
-
Mar 28, 2026, 16:42Kalpana Gupta Shekhawat: Low Ferritin and Its Impact on Dopamine Signaling